Flex Pharma, Inc. is a biotechnology company. The Company develops treatments for nocturnal leg cramps, muscle cramps and spasms associated with severe neuromuscular conditions, and exercise associated muscle cramps (EAMCs). The Company's product candidates activate certain receptors in primary sensory neurons, which then act through neuronal circuits to reduce the repetitive firing, or hyperexcitability, of alpha-motor neurons in the spinal cord, thereby preventing or reducing the frequency and intensity of muscle cramps and spasms. The Company operates through developing and commercializing products for nocturnal leg cramps, muscle cramps, spasms and spasticity associated with severe neuromuscular conditions, and exercise-associated muscle cramps segment. The Company's lead drug product candidate is FLX-787, which is in the Phase II clinical trial stage. It is developing a consumer brand and products specifically formulated to treat athletes suffering from EAMCs.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Bio Therapeutic Drugs
- Sub-Industry: N/A
- Symbol: NASDAQ:FLKS
- CUSIP: N/A
- Web: www.flex-pharma.com
Capitalization:- Market Cap: $61.82 million
- Outstanding Shares: 17,285,000
Average Prices:- 50 Day Moving Avg: $3.46
- 200 Day Moving Avg: $3.46
- 52 Week Range: $3.28 - $11.99
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -1.67
- P/E Growth: 0.00
Sales & Book Value:- Annual Revenue: $1.48 million
- Price / Sales: 41.58
- Book Value: $2.58 per share
- Price / Book: 1.38
Profitability:- EBIDTA: ($35,580,000.00)
- Net Margins: -2,410.97%
- Return on Equity: -64.15%
- Return on Assets: -59.78%
Debt:- Current Ratio: 9.75%
- Quick Ratio: 9.62%
Misc:- Average Volume: 15,557 shs.
- Beta: 3.36
- Short Ratio: 1.22
Frequently Asked Questions for Flex Pharma (NASDAQ:FLKS)
What is Flex Pharma's stock symbol?
Flex Pharma trades on the NASDAQ under the ticker symbol "FLKS."
How were Flex Pharma's earnings last quarter?
Flex Pharma, Inc. (NASDAQ:FLKS) posted its earnings results on Wednesday, August, 2nd. The company reported ($0.51) earnings per share for the quarter, beating the consensus estimate of ($0.63) by $0.12. The company had revenue of $0.34 million for the quarter, compared to analyst estimates of $0.46 million. Flex Pharma had a negative net margin of 2,410.97% and a negative return on equity of 64.15%. View Flex Pharma's Earnings History.
When will Flex Pharma make its next earnings announcement?
Where is Flex Pharma's stock going? Where will Flex Pharma's stock price be in 2017?
6 equities research analysts have issued 12-month price targets for Flex Pharma's stock. Their predictions range from $8.00 to $40.00. On average, they anticipate Flex Pharma's stock price to reach $16.80 in the next twelve months. View Analyst Ratings for Flex Pharma.
Who are some of Flex Pharma's key competitors?
Some companies that are related to Flex Pharma include Synthetic Biologics (SYN), Cidara Therapeutics (CDTX), Summit Therapeutics PLC (SUMM), Aldeyra Therapeutics (ALDX), MaxCyte (MXCT), Galmed Pharmaceuticals (GLMD), Gemphire Therapeutics (GEMP), MEI Pharma (MEIP), Otonomy (OTIC), Intec Pharma (NTEC), Affimed N.V. (AFMD), Zafgen (ZFGN), Ophthotech Corporation (OPHT), ProNAi Therapeutics (SRRA), Lipocine (LPCN), ADMA Biologics (ADMA), Dicerna Pharmaceuticals (DRNA) and Aeglea BioTherapeutics (AGLE).
Who are Flex Pharma's key executives?
Flex Pharma's management team includes the folowing people:
- Christoph H. Westphal M.D. Ph.D., Chairman of the Board
- William K. McVicar Ph.D., President, Chief Executive Officer, Director
- John McCabe, Chief Financial Officer, Treasurer
- Kathie Lindemann, Chief Operating Officer
- Jennifer Cermak Ph.D., Vice President - Research & Development
- Robert Hadfield Ph.D., General Counsel, Secretary
- Elizabeth Woo M.D. Ph.D., Senior Vice President, Investor Relations and Corporate Communications
- Thomas C. Wessel M.D. Ph.D., Chief Medical Officer
- Jeffrey D. Capello, Director
- Roderick Mackinnon M.D, Director
When did Flex Pharma IPO?
(FLKS) raised $60 million in an initial public offering on Thursday, January 29th 2015. The company issued 4,600,000 shares at a price of $12.00-$14.00 per share. Jefferies and Piper Jaffray served as the underwriters for the IPO and JMP Securities, Cantor Fitzgerald and Roth Capital Partners were co-managers.
Who owns Flex Pharma stock?
Flex Pharma's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Ameriprise Financial Inc. (3.82%), Franklin Resources Inc. (2.64%), Royce & Associates LP (1.82%), C WorldWide Group Holding A S (1.63%), Vanguard Group Inc. (1.55%) and FMR LLC (1.27%). Company insiders that own Flex Pharma stock include Christoph H Westphal, John P Mccabe, Marc D Kozin, Michelle Stacy, Roderick Mackinnon and Thomas Wessel. View Institutional Ownership Trends for Flex Pharma.
Who sold Flex Pharma stock? Who is selling Flex Pharma stock?
Who bought Flex Pharma stock? Who is buying Flex Pharma stock?
Flex Pharma's stock was acquired by a variety of institutional investors in the last quarter, including Ameriprise Financial Inc., Royce & Associates LP and LMR Partners LLP. Company insiders that have bought Flex Pharma stock in the last two years include Christoph H Westphal, John P Mccabe, Marc D Kozin, Michelle Stacy, Roderick Mackinnon and Thomas Wessel. View Insider Buying and Selling for Flex Pharma.
How do I buy Flex Pharma stock?
Shares of Flex Pharma can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Flex Pharma's stock price today?
One share of Flex Pharma stock can currently be purchased for approximately $3.56.
MarketBeat Community Rating for Flex Pharma (NASDAQ FLKS)MarketBeat's community ratings are surveys of what our community members think about Flex Pharma and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Flex Pharma (NASDAQ:FLKS) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 1 Hold Rating, 5 Buy Ratings |
| Consensus Rating: | Buy (Score: 2.83) |
| Consensus Price Target: | $16.80 (371.91% upside) |
Analysts' Ratings History for Flex Pharma (NASDAQ:FLKS)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 9/7/2017 | Roth Capital | Initiated Coverage | Buy | $14.00 | Low |  |
| 5/4/2017 | Jefferies Group LLC | Lower Price Target | Buy | $9.00 -> $8.00 | High | |
| 3/8/2017 | Piper Jaffray Companies | Set Price Target | Buy | $12.00 | Low | |
| 11/3/2016 | JMP Securities | Reiterated Rating | Buy | | N/A | |
| 11/2/2016 | Cantor Fitzgerald | Set Price Target | Hold | $10.00 | N/A | |
| 10/15/2016 | HC Wainwright | Reiterated Rating | Buy | $40.00 | N/A | |
(Data available from 9/21/2015 forward)
Earnings History for Flex Pharma (NASDAQ:FLKS)Earnings History by Quarter for Flex Pharma (NASDAQ FLKS)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 10/31/2017 | | ($0.60) | | | | | N/A | |
| 8/2/2017 | Q2 2017 | ($0.63) | ($0.51) | $0.46 million | $0.34 million | View | Listen | |
| 5/3/2017 | Q1 2017 | ($0.62) | ($0.49) | $0.38 million | $0.24 million | View | Listen | |
| 3/8/2017 | Q4 2016 | ($0.84) | ($0.48) | $0.09 million | $0.30 million | View | Listen | |
| 11/2/2016 | Q316 | ($0.72) | ($0.65) | $0.15 million | $0.60 million | View | Listen | |
| 8/3/2016 | Q216 | ($0.67) | ($0.71) | $0.01 million | $0.11 million | View | Listen | |
| 5/4/2016 | Q1 | ($0.56) | ($0.61) | | | View | Listen | |
| 3/8/2016 | Q415 | ($0.56) | ($0.51) | | | View | Listen | |
| 11/4/2015 | Q315 | ($0.44) | ($0.53) | | | View | Listen | |
| 8/5/2015 | Q215 | ($0.37) | ($0.47) | | | View | Listen | |
| 5/6/2015 | Q1 | ($0.32) | ($0.59) | | | View | Listen | |
| 3/17/2015 | Q4 | ($0.12) | ($1.82) | | | View | Listen | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Flex Pharma (NASDAQ:FLKS)2017 EPS Consensus Estimate: ($2.03)
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 1 | ($0.39) | ($0.39) | ($0.39) |
| Q2 2017 | 1 | ($0.46) | ($0.46) | ($0.46) |
| Q3 2017 | 1 | ($0.56) | ($0.56) | ($0.56) |
| Q4 2017 | 1 | ($0.62) | ($0.62) | ($0.62) |
(Data provided by Zacks Investment Research)
Dividend History for Flex Pharma (NASDAQ:FLKS)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Flex Pharma (NASDAQ:FLKS)Insider Ownership Percentage: 45.36%
Institutional Ownership Percentage: 27.74%
Insider Trades by Quarter for Flex Pharma (NASDAQ:FLKS)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 11/8/2016 | Christoph H Westphal | Insider | Buy | 7,000 | $7.31 | $51,170.00 | |
| 11/7/2016 | Christoph H Westphal | Insider | Buy | 8,870 | $5.70 | $50,559.00 | |
| 11/7/2016 | John P Mccabe | VP | Buy | 1,650 | $6.01 | $9,916.50 | |
| 6/23/2016 | Christoph H Westphal | CEO | Buy | 2,700 | $11.28 | $30,456.00 | |
| 6/22/2016 | Christoph H Westphal | CEO | Buy | 5,700 | $11.05 | $62,985.00 | |
| 6/21/2016 | Christoph H Westphal | CEO | Buy | 2,800 | $11.07 | $30,996.00 | |
| 6/20/2016 | Christoph H Westphal | CEO | Buy | 6,000 | $11.18 | $67,080.00 | |
| 6/16/2016 | Christoph H Westphal | CEO | Buy | 5,800 | $11.17 | $64,786.00 | |
| 6/14/2016 | Christoph H Westphal | CEO | Buy | 5,900 | $11.54 | $68,086.00 | |
| 6/10/2016 | Christoph H Westphal | CEO | Buy | 6,000 | $11.94 | $71,640.00 | |
| 6/8/2016 | Christoph H Westphal | CEO | Buy | 5,900 | $12.25 | $72,275.00 | |
| 6/6/2016 | Christoph H Westphal | CEO | Buy | 6,000 | $12.56 | $75,360.00 | |
| 6/2/2016 | Christoph H Westphal | CEO | Buy | 10,000 | $12.99 | $129,900.00 | |
| 5/31/2016 | Christoph H Westphal | CEO | Buy | 22,300 | $12.68 | $282,764.00 | |
| 5/26/2016 | Christoph H Westphal | CEO | Buy | 28,600 | $12.84 | $367,224.00 | |
| 5/24/2016 | Christoph H Westphal | CEO | Buy | 30,334 | $12.42 | $376,748.28 | |
| 5/20/2016 | Christoph H Westphal | CEO | Buy | 7,914 | $11.06 | $87,528.84 | |
| 5/18/2016 | Christoph H Westphal | CEO | Buy | 33,400 | $11.10 | $370,740.00 | |
| 5/16/2016 | Christoph H Westphal | CEO | Buy | 15,469 | $10.25 | $158,557.25 | |
| 5/12/2016 | Christoph H Westphal | CEO | Buy | 30,217 | $10.12 | $305,796.04 | |
| 5/10/2016 | Christoph H Westphal | CEO | Buy | 30,109 | $9.94 | $299,283.46 | |
| 3/24/2016 | Christoph H Westphal | CEO | Buy | 49,563 | $11.06 | $548,166.78 | |
| 3/22/2016 | Christoph H Westphal | CEO | Buy | 23,951 | $11.78 | $282,142.78 | |
| 3/21/2016 | Christoph H Westphal | CEO | Buy | 48,058 | $11.74 | $564,200.92 | |
| 3/18/2016 | Christoph H Westphal | CEO | Buy | 37,574 | $11.00 | $413,314.00 | |
| 3/16/2016 | Christoph H Westphal | CEO | Buy | 38,379 | $10.23 | $392,617.17 | |
| 3/15/2016 | Michelle Stacy | Director | Buy | 2,585 | $9.63 | $24,893.55 | |
| 3/14/2016 | Thomas Wessel | Insider | Buy | 20,000 | $7.94 | $158,800.00 | |
| 3/11/2016 | Christoph H Westphal | CEO | Buy | 89,680 | $7.00 | $627,760.00 | |
| 3/11/2016 | Roderick Mackinnon | Director | Buy | 10,000 | $7.03 | $70,300.00 | |
| 12/14/2015 | Christoph H Westphal | CEO | Buy | 927 | $12.01 | $11,133.27 | |
| 12/7/2015 | Christoph H Westphal | CEO | Buy | 907 | $12.02 | $10,902.14 | |
| 11/19/2015 | Marc D Kozin | Director | Buy | 4,500 | $11.38 | $51,210.00 | |
| 11/16/2015 | Christoph H Westphal | CEO | Buy | 1,001 | $10.78 | $10,790.78 | |
| 11/9/2015 | Christoph H Westphal | CEO | Buy | 1,000 | $11.03 | $11,030.00 | |
| 10/26/2015 | Christoph H Westphal | CEO | Buy | 1,043 | $10.55 | $11,003.65 | |
| 10/19/2015 | Christoph H Westphal | CEO | Buy | 1,018 | $10.61 | $10,800.98 | |
| 9/28/2015 | Christoph H Westphal | CEO | Buy | 924 | $11.18 | $10,330.32 | |
| 3/30/2015 | Christoph H Westphal | CEO | Buy | 272 | $20.52 | $5,581.44 | |
(Data available from 1/1/2013 forward)
Headline Trends for Flex Pharma (NASDAQ:FLKS)
Latest Headlines for Flex Pharma (NASDAQ:FLKS)
| Source: |
|
| Date | Headline |
|---|
 | Flex Pharma, Inc. (FLKS) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - September 16 at 11:02 AM |
| Zacks: Analysts Expect Flex Pharma, Inc. (FLKS) to Post -$0.62 Earnings Per Share
www.americanbankingnews.com - September 13 at 9:30 AM |
| Flex Pharma, Inc. (FLKS) Coverage Initiated at Roth Capital
www.americanbankingnews.com - September 7 at 8:58 PM |
 | Flex Pharma Presenting at Upcoming Investor Conferences in September 2017
finance.yahoo.com - September 6 at 6:35 PM |
| ETFs with exposure to Flex Pharma, Inc. : September 1, 2017
finance.yahoo.com - September 2 at 12:00 AM |
| $500,000.00 in Sales Expected for Flex Pharma, Inc. (FLKS) This Quarter
www.americanbankingnews.com - August 27 at 4:46 AM |
| Zacks: Brokerages Anticipate Flex Pharma, Inc. (FLKS) Will Post Earnings of -$0.68 Per Share
www.americanbankingnews.com - August 25 at 10:04 PM |
| Flex Pharma, Inc. :FLKS-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017
finance.yahoo.com - August 24 at 8:06 PM |
| Cantor Fitzgerald Weighs in on Flex Pharma, Inc.'s FY2017 Earnings (NASDAQ:FLKS)
www.americanbankingnews.com - August 10 at 9:10 AM |
| Flex Pharma, Inc. (NASDAQ:FLKS) Expected to Post Quarterly Sales of $500,000.00
www.americanbankingnews.com - August 9 at 7:24 AM |
| Flex Pharma, Inc. (FLKS) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - August 7 at 7:30 PM |
| Zacks: Brokerages Expect Flex Pharma, Inc. (NASDAQ:FLKS) to Post -$0.68 EPS
www.americanbankingnews.com - August 7 at 12:12 PM |
| Jefferies Group Comments on Flex Pharma, Inc.'s FY2017 Earnings (NASDAQ:FLKS)
www.americanbankingnews.com - August 7 at 7:46 AM |
| Edited Transcript of FLKS earnings conference call or presentation 2-Aug-17 12:45pm GMT
finance.yahoo.com - August 3 at 4:01 PM |
| Flex Pharma, Inc. (FLKS) Posts Quarterly Earnings Results, Beats Estimates By $0.12 EPS
www.americanbankingnews.com - August 3 at 2:52 PM |
| Investor Network: Flex Pharma, Inc. to Host Earnings Call
finance.yahoo.com - August 2 at 7:37 PM |
| Flex Pharma Reports Second Quarter 2017 Financial Results
finance.yahoo.com - August 2 at 7:37 PM |
| Flex Pharma reports 2Q loss
finance.yahoo.com - August 2 at 7:37 PM |
| Flex Pharma Initiates ALS Phase 2 Trial with FLX-787 in US
finance.yahoo.com - August 1 at 7:17 PM |
| Flex Pharma Names William McVicar President and Chief Executive Officer
finance.yahoo.com - July 31 at 6:25 PM |
| Flex Pharma, Inc. (NASDAQ:FLKS) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - July 28 at 10:49 AM |
| Corporate News Blog - FDA Grants Fast Track Designation to Flex Pharma’s FLX-787 for the Treatment of Severe Muscle Cramps Associated with ALS
finance.yahoo.com - July 27 at 7:14 PM |
| Flex Pharma to Report Second Quarter 2017 Results on August 2, 2017
finance.yahoo.com - July 27 at 12:17 AM |
| FDA Grants Fast Track Designation to Flex Pharma’s FLX-787 for the Treatment of Severe Muscle Cramps Associated with ALS
finance.yahoo.com - July 25 at 6:57 PM |
| $460,000.00 in Sales Expected for Flex Pharma, Inc. (FLKS) This Quarter
www.americanbankingnews.com - July 20 at 1:46 PM |
| Flex Pharma, Inc. (NASDAQ:FLKS) Short Interest Down 56.7% in June
www.americanbankingnews.com - July 16 at 7:08 AM |
| Flex Pharma, Inc. (NASDAQ:FLKS) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - July 3 at 11:24 AM |
 | HOTSHOT Partners With IRONMAN To Help Athletes Prevent Muscle Cramping
www.bizjournals.com - June 29 at 4:21 AM |
| Flex Pharma, Inc. (FLKS) Expected to Announce Quarterly Sales of $460,000.00
www.americanbankingnews.com - June 24 at 10:40 AM |
| Brokerages Expect Flex Pharma, Inc. (FLKS) to Post -$0.63 Earnings Per Share
www.americanbankingnews.com - June 22 at 8:18 AM |
| Flex Pharma Inc (FLKS) Given Consensus Rating of "Buy" by Analysts
www.americanbankingnews.com - June 6 at 8:42 AM |
| Flex Pharma Announces Executive Leadership Transition
finance.yahoo.com - June 5 at 5:20 PM |
| Flex Pharma Inc (FLKS) Short Interest Down 10.4% in May
www.americanbankingnews.com - June 4 at 8:20 AM |
 | Flex Pharma (FLKS) Announces Endorsement of Phase 2 Trial with FLX-787 in Charcot-Marie-Tooth by Inherited Neuropathies Consortium
www.streetinsider.com - June 2 at 6:33 PM |
| Flex Pharma’s Phase 2 Trial with FLX-787 in Charcot-Marie-Tooth Endorsed by the Inherited Neuropathies Consortium
finance.yahoo.com - June 2 at 8:19 AM |
| Flex Pharma Presenting at Upcoming Investor Conferences in June 2017
finance.yahoo.com - May 30 at 11:16 AM |
| Flex Pharma Inc (FLKS) Expected to Post Quarterly Sales of $460,000.00
www.americanbankingnews.com - May 28 at 7:48 AM |
| -$0.74 Earnings Per Share Expected for Flex Pharma Inc (FLKS) This Quarter
www.americanbankingnews.com - May 27 at 12:30 AM |
| Flex Pharma Inc (FLKS) Downgraded to "Sell" at Zacks Investment Research
www.americanbankingnews.com - May 23 at 8:43 PM |
| Flex Pharma Inc (FLKS) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - May 12 at 8:48 AM |
| Flex Pharma Inc Expected to Earn Q2 2017 Earnings of ($0.46) Per Share (FLKS)
www.americanbankingnews.com - May 8 at 8:21 AM |
| Flex Pharma Inc (FLKS) Expected to Announce Quarterly Sales of $530,000.00
www.americanbankingnews.com - May 5 at 3:14 PM |
| Flex Pharma Inc (FLKS) Receives "Buy" Rating from Jefferies Group LLC
www.americanbankingnews.com - May 4 at 1:21 PM |
| Edited Transcript of FLKS earnings conference call or presentation 3-May-17 12:45pm GMT
finance.yahoo.com - May 4 at 12:23 PM |
| Flex Pharma (FLKS) Earning Somewhat Positive Media Coverage, Study Shows
www.americanbankingnews.com - May 4 at 1:21 AM |
| Flex Pharma Inc (FLKS) Releases Quarterly Earnings Results, Beats Estimates By $0.13 EPS
www.americanbankingnews.com - May 3 at 6:26 PM |
| Flex Pharma Inc (FLKS) Expected to Post Earnings of -$0.63 Per Share
www.americanbankingnews.com - May 3 at 2:06 PM |
| Flex Pharma Reports First Quarter 2017 Financial Results
finance.yahoo.com - May 3 at 10:25 AM |
| Flex Pharma reports 1Q loss
finance.yahoo.com - May 3 at 10:25 AM |
| Flex Pharma (FLKS) Given Daily News Impact Rating of -0.08
www.americanbankingnews.com - April 30 at 11:57 AM |
Flex Pharma (FLKS) Chart for Thursday, September, 21, 2017
